₹ 14700 / 105 shares
₹ 152.46 Cr
Retail Gain/Listing Gain
Valiant Laboratories Limited is an active pharmaceutical ingredient (API)/bulk drug manufacturing company, with a focus on manufacturing Paracetamol. Bulk drugs/APIs serve as raw materials for manufacturing finished dosage forms or formulations.
India is the largest provider of generic drugs, globally contributing to approximately 20% of global supply by volume of generic drugs. The overall API industry in India grew from Rs. 781 billion in fiscal 2017 to Rs. 1,179 billion in fiscal 2022, registering a CAGR of 8.5% in rupee terms. Going forward, the API industry is expected to grow at a rate of 9-11% between fiscal 2022 and 2027, largely driven by the increase in API exports. More specifically, the paracetamol API industry (domestic + exports) grew from Rs. 22 billion in fiscal 2017 to Rs. 39 billion in fiscal 2023.
Here are the key financials for Valiant Laboratories Limited:
Particulars (in Rs. million)
How to apply for IPO through ASBA
The Valiant Laboratories Limited IPO has an issue size of Rs. 152.46 crores. The IPO opens for subscription on 27th September and closes on 3rd October 2023.
Link Intime India Private Limited is the registrar for this IPO.